Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM

References

• Oh J, Vidal JA, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018;31(6):752–759.
   PubMed Web of Science ®Google Scholar
• Calabresi P, Kieseier B, Arnold D, et al. ADVANCE study investigators. pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13(7):657–665.
   PubMed Web of Science ®Google Scholar
• Kappos L, Edan G, MS F, et al. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology. 2016;87(10):978–987.
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal Med. 2006;354(9):899–910.
   PubMed Web of Science ®Google Scholar
• Rae-Grant A, GS D, RA M, et al. Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):789–800.
   PubMed Web of Science ®Google Scholar
• Bsteh G, Feige J, Ehling R, et al. Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors. Mult Scler. 2017;23(9):1241–1248.
   PubMed Web of Science ®Google Scholar
• WO T, BG W. Stopping immunomodulatory medications in MS: frequency, reasons and consequences. Multiple Sclerosis Related Disorders. 2015;4(5):437–443
   PubMed Web of Science ®Google Scholar
• Kappos L. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352(9139):1491–1497.
   PubMed Web of Science ®Google Scholar
• Berkovich R. Clinical and MRI outcomes after stopping or switching disease-modifying therapy in stable MS patients: a case series report. Mult Scler Relat Disord. 2017;17:123–127.
   PubMed Web of Science ®Google Scholar
• Evans C, Tam J, Kingwell E, et al. Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study. Clin Ther. 2012;34(2):341–350.
   PubMed Web of Science ®Google Scholar
• Grytten N, Jh A, Espeset K, et al. Stoppers and non-starters of disease-modifying treatment in multiple sclerosis. Acta Neurol Scand. 2013;127(2):133–140.
   PubMed Web of Science ®Google Scholar
• Rojas JI, Carrá A, Correale J, et al. The Argentinean multiple sclerosis registry (RelevarEM): methodological aspects and directions. Mult Scler Relat Disord. 2019;32:133–137.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173.
   PubMed Web of Science ®Google Scholar
• Fd L, SC R, JA C, et al. Defining the clinical course of multiple sclerosis. Neurology. 2014;83(3):278–286.
   PubMed Web of Science ®Google Scholar
• KE H, Liang K, Cossburn MD, et al. Long-term outcome of paediatric-onset multiple sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2013;84(2):141–147.
   PubMed Web of Science ®Google Scholar
• Cm P, Dw P, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227–231.
   PubMed Web of Science ®Google Scholar
• Drucker E, SH V. Estimating population prevalence of human immunodeficiency virus infection in urban areas with high rates of intravenous drug use: a model of the Bronx in 1988. Am J Epidemiol. 1989;130(1):133–142.
   PubMed Web of Science ®Google Scholar
• Birnbaum G. Stopping disease-modifying therapy in nonrelapsing multiple sclerosis. Int J MS Care. 2017;19:11–14.
   PubMedGoogle Scholar
• Siger M, Durko A, Nicpan A, et al. Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity. J Neurol Sci. 2011;303(1–2):50–52.
   PubMed Web of Science ®Google Scholar
• Kister I, Spelman T, Alroughani R. Alroughani R, et al. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. J Neurol Neurosurg Psychiatry. 2016;87(10):1133–1137.
   PubMed Web of Science ®Google Scholar
• Pasca M, Forci B, Mariottini A, et al. Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021;47:102591.
   PubMed Web of Science ®Google Scholar
• Wong J, Gomes T, Mamdani M, et al. Adherence MS Ontario 2011. Can J Neurol Sci. 2011;38(3):429–433.
   PubMed Web of Science ®Google Scholar
• Dc M, Likosky W, AC B, et al. Side effect profile and adherence to in the treatment of Multiple Sclerosis with interferon beta-la. Mult Scler. 1998;4(6):487–489.
   PubMed Web of Science ®Google Scholar
• Río J, Tintoré M, Nos C, et al. Interferon beta in relapsing–remitting multiple sclerosis. J Neurol. 2005;252(7):795–800.
   PubMed Web of Science ®Google Scholar
• Tortorella C, Bellacosa A, Paolicelli D, et al. Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. J Neurol Sci. 2005;239(1):95–99.
   PubMed Web of Science ®Google Scholar
• Tremlett H, Zhao Y, Joseph J, et al. Relapses in multiple sclerosis are age and time dependent. J Neurol Neurosurg Psychiatry. 2008;79(12):1368–1374.
   PubMed Web of Science ®Google Scholar
• Yano H, Gonzalez C, Bc H, et al. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: effect on clinical and MRI outcomes. Mult Scler Relat Disord. 2019;35:119–127.
   PubMed Web of Science ®Google Scholar
• Monschein T, Salhofer S, Patrick P, et al. Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis. J Neurol. 2021;268(4):1247–1253.
   PubMed Web of Science ®Google Scholar
• LH H, TH F, Conway D, et al. Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60. Mult Scler J. 2019;25(5):699–708.
   PubMed Web of Science ®Google Scholar
• Wu X, Dastidar P, Kuusisto H, et al. Increased disability and MRI lesions after discontinuation of IFN-β-1a in secondary progressive MS. Acta Neurol Scand. 2005;112(4):242–247.
   PubMed Web of Science ®Google Scholar
• Bonenfant J, Bajeux E, Deburghgraeve V, et al. Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis? Eur J Neurol. 2016;24(2):237–244.
   PubMed Web of Science ®Google Scholar